BenzingaSeptember 1, 2026 at 3:31 AM NY3 days ago
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga
Companies in This Story
Related Stories
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Yahoo3 hours ago
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill1 hour ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill2 hours ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo3 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo3 hours ago